Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

NCT ID: NCT04057807

Last Updated: 2024-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-15
• Study Completion Date: 2022-07-27

Brief Summary

To examine the differences in the capacity to activate microglia in patients with Alzheimer's Disease (AD) compared to age-comparable cognitively normal subjects and younger healthy controls.

Detailed Description

The primary outcome is Microglia Activation Reserve Index (MARI) (calculated in the parietal region of interest (ROIs)) in AD patients compared to elderly controls. The researchers will recruit up to 20 participants. The investigators will use 7 AD and 7 comparably aged cognitively normal successfully scanned subjects to calculate the microglial activation reserve index. The expectations are significant differences between the two groups suggesting altered reactivity of the microglia in AD. The result would be an exciting one suggesting at least one mechanism by which some patients with significant amyloid load have progressive dementia while comparable others are either cognitively normal or have stable Mild Cognitive Impairment (MCI). It will also suggest avenues for intervention in amyloid positive MCIs to prevent progression to Alzheimer's dementia. The exploratory analysis will include:

1. Effects of aging on MARI: The researchers will evaluate the effects of aging on MARI. Comparisons will be made for MARI between cognitively normal elderly and the 8 healthy individuals to whom the investigators applied this protocol in an earlier study. The reactivity of microglia is reported to change with age and so the investigators expect MARI to change in the cognitively normal elderly. However, the expectation is that the differences between the young and elderly cognitively normal subjects to be small relative to the comparison of AD and elderly normal controls.

2. Effects of amyloid on MARI: The researchers will look at the relationship of regional and global amyloid load to MARI. The presence of a relationship suggests that one of the reasons for altered microglial reactivity might be interactions of microglia with pathologic amyloid.

3. Effects of MARI on cognition: The researchers will explore whether MARI would correlate with the measure of disease stage, with higher MARIs associated with worse neuropsychological score and more severe disease. The researchers will look for correlations between MARI and the individual neuropsychological scores. This would determine if disease severity is correlated with microglial activation reserve.

Conditions

Alzheimer Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patients receiving endotoxin

The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously

Group Type: EXPERIMENTAL

LPS

Intervention Type: DRUG

LPS (0.4 ng/kg)

Interventions

LPS

LPS (0.4 ng/kg)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Mild AD Subjects:
• National Institute on Aging (NIA)-Alzheimer's Association core clinical criteria for probable AD
• Age between 55 and 90 (inclusive)
• Score on the Montreal Cognitive Assessment (MOCA) greater than or equal to 17
• Presence of a responsible caregiver who will accompany AD subjects to all procedures.
• Biomarker evidence of Alzheimer's disease via an amyloid PET scan or cerebrospinal fluid (CSF) amyloid Beta measurement.
• The patient should have the capacity to consent.
• Clinical Dementia Rating (CDR) global score greater than 0.
• Cognitively normal elderly Subjects:
• Absence of National Institute on Aging-Alzheimer's Association core clinical criteria for probable AD
• Objective memory scores within the normal range for age (do not meet MCI Subjects criterion 2)
• Age between 55 and 90 (inclusive)
• Clinical Dementia Rating (CDR) global score of 0.0

Exclusion Criteria

• Any significant neurologic disease (other than probable AD in the AD Subjects group), such as stroke, Parkinson's disease, brain tumor, seizure disorder, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits.
• Any significant systemic disease including hepatic failure, heart failure, renal failure, chronic obstructive pulmonary disease (COPD), active infection and autoimmune disease.
• Screening/baseline MRI scan with evidence of infection, infarction, or other focal lesions. Subjects with multiple lacunes or lacunes in a critical memory structure are excluded.
• Any significant systemic illness or unstable medical condition, including uncontrolled or insulin- dependent diabetes mellitus, uncorrected hypothyroidism or hyperthyroidism, or systemic cancer.
• Current or regular use of over-the-counter medication that may affect the immune system (e.g., ibuprofen), including corticosteroids or immunosuppressant drugs; no use in 3 weeks prior to the PET scan
• Investigational agents are prohibited 4 weeks prior to entry and for the duration of the study.
• Previous treatment with an investigational small molecule with anti-amyloid properties or passive immunization against amyloid within 1 year of study entry.
• Previous treatment with an active immunization against amyloid.
• History of schizophrenia or other major psychiatric disorder (DSM IV criteria).
• History of alcohol or substance abuse or dependence (DSM IV criteria) within the past 2 years.
• Clinically significant abnormalities on screening laboratory tests (B12, Thyroid function tests, hematology, chemistry, urinalysis, ECG).
• Pregnancy, as determined by screening pregnancy tests for pre-menopausal females
• Impairment of visual or auditory acuity sufficient to interfere with study procedures.
• Education level < 6 years.
• Evidence of current depression as defined by a score of ≥ 5 on the Geriatric Depression Scale.
• Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body. The presence of claustrophobia, precluding MRI.
• Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1.
• Vaccination in the last month.
• Drink more than 5 alcoholic drinks per week or any heavy drinking days in the last 30 days.
• BMI > 35 or < 19
• Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or Intrauterine Device (IUD)
• Individuals who are classified as "low binders" for the rs6971 polymorphism (<10% of the population)
• Patients on antiplatelet and anticoagulant medications will be excluded.
• Any patient without the capacity to consent will be excluded.
• Unstable hypertension. If blood pressure is greater than 160/100, the investigators will contact the subject's primary care physician to manage their blood pressure. If their blood pressure is not reduced to be consistently below 160/100 by the scanning day the subject will be excluded from the protocol.
• Patients with contraindications for lumbar puncture procedure can be still involved and will be excluded from the optional portion of the study with the lumbar puncture. These include existing intracranial space-occupying lesion with mass effect, posterior fossa mass, risk of cerebral herniation by increased CSF pressure or Arnold chiari malformation, as well as anticoagulant medication, coagulopathies and uncorrected bleeding diathesis, congenital spine abnormalities, and local skin infection at the puncture site.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

Yale University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adam Mecca, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Alzheimer's Disease Research Unit

New Haven, Connecticut, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

1K23AG057794-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1611018611

Identifier Type: -

Identifier Source: org_study_id